IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
- PMID: 25900158
- PMCID: PMC7202429
- DOI: 10.1093/jac/dkv085
IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
Abstract
Objectives: Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with significant mortality. We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates.
Methods: We retrospectively analysed 32 patients with confirmed MERS-CoV infection, admitted between April 2014 and June 2014, by positive respiratory sample RT-PCR. Plasma MERS-CoV RT-PCR was performed at the time of diagnosis for 19 patients.
Results: The overall mortality rate was 69% (22/32). Ninety percent (9/10) of patients with positive plasma MERS-CoV PCR died compared with 44% (4/9) of those with negative plasma MERS-CoV PCR. Mortality rate in patients who received IFN-α2a was 85% (11/13) compared with 64% (7/11) in those who received IFN-β1a (P = 0.24). The mortality rate in patients with renal failure (14), including 8 on haemodialysis, was 100%. Age >50 years and diabetes mellitus were found to be significantly associated with mortality (OR = 26.1; 95% CI 3.58-190.76; P = 0.001 and OR = 15.74; 95% CI 2.46-100.67; P = 0.004, respectively). The median duration of viral shedding in patients who recovered was 11 days (range 6-38 days). Absence of fever was noted in 5/32 patients.
Conclusions: Plasma MERS-CoV RT-PCR may serve as an effective tool to predict MERS-CoV-associated mortality. Older age and comorbid conditions may have contributed to the lack of efficacy of IFN-α2a or IFN-β1a with ribavirin in treating MERS-CoV. Absence of fever should not exclude MERS-CoV.
Keywords: MERS-CoV; interferon; treatment.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study.Clin Infect Dis. 2020 Apr 15;70(9):1837-1844. doi: 10.1093/cid/ciz544. Clin Infect Dis. 2020. PMID: 31925415 Free PMC article.
-
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.BMC Infect Dis. 2019 Oct 22;19(1):870. doi: 10.1186/s12879-019-4555-5. BMC Infect Dis. 2019. PMID: 31640578 Free PMC article.
-
Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia.Ann Saudi Med. 2014 Sep-Oct;34(5):396-400. doi: 10.5144/0256-4947.2014.396. Ann Saudi Med. 2014. PMID: 25827696 Free PMC article.
-
Successful recovery of MERS CoV pneumonia in a patient with acquired immunodeficiency syndrome: a case report.J Clin Virol. 2015 Jan;62:69-71. doi: 10.1016/j.jcv.2014.11.030. Epub 2014 Nov 29. J Clin Virol. 2015. PMID: 25542475 Free PMC article. Review.
-
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.Curr Opin Pulm Med. 2014 May;20(3):233-41. doi: 10.1097/MCP.0000000000000046. Curr Opin Pulm Med. 2014. PMID: 24626235 Review.
Cited by
-
[Use of ribavirin in viruses other than hepatitis C. A review of the evidence].Enferm Infecc Microbiol Clin. 2019 Nov;37(9):602-608. doi: 10.1016/j.eimc.2018.05.008. Epub 2018 Jun 12. Enferm Infecc Microbiol Clin. 2019. PMID: 38620198 Free PMC article. Review. Spanish.
-
Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2.Oxf Open Immunol. 2023 Jan 10;4(1):iqad001. doi: 10.1093/oxfimm/iqad001. eCollection 2023. Oxf Open Immunol. 2023. PMID: 37051070 Free PMC article. Review.
-
Heterogeneity of treatment effect of interferon-β1b and lopinavir-ritonavir in patients with Middle East respiratory syndrome by cytokine levels.Sci Rep. 2022 Oct 28;12(1):18186. doi: 10.1038/s41598-022-22742-8. Sci Rep. 2022. PMID: 36307462 Free PMC article. Clinical Trial.
-
Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.RSC Adv. 2020 Jul 17;10(45):26895-26916. doi: 10.1039/d0ra05821a. eCollection 2020 Jul 15. RSC Adv. 2020. PMID: 35515773 Free PMC article. Review.
-
'Convalescent Plasma'- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review.Infect Disord Drug Targets. 2022;22(8):42-60. doi: 10.2174/1871526522666220425103031. Infect Disord Drug Targets. 2022. PMID: 35469582
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous